.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Harvard Business School
Farmers Insurance
Colorcon
McKesson
Fuji
Baxter
Cantor Fitzgerald
AstraZeneca
Accenture

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Cell permeable inhibitors of anaphase promoting complex
Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.
Inventor(s): King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:14/276,994
Patent Claims:1. A synergistic composition comprising a prodrug of tosyl-L-arginine methylester (TAME) and apcin or an analog or derivative thereof, wherein the prodrug of TAME is proTAME: ##STR00005## and wherein the apcin comprises ##STR00006## wherein said composition diffuses across the plasma membrane of a cell.

2. The composition of claim 1, wherein said prodrug is characterized as having a eukaryotic cell permeability level at least 20% greater than that of TAME.

3. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutical carrier.

4. The composition of claim 1, wherein said cell is eukaryotic, mammalian, or human.

5. The composition of claim 1, wherein said prodrug of TAME inhibits an activity of an anaphase promoting complex (APC).

6. A synergistic formulation comprising an amount of: a) a prodrug of tosyl-L-arginine methylester (TAME), and b) apcin, that is sufficient to inhibit the degradation of a substrate of an anaphase-promoting complex/cyclosome (APC) for arresting the mitotic cycle of a cell, wherein said prodrug of TAME is proTAME: ##STR00007## and wherein said apcin is ##STR00008##

7. The formulation of claim 6, further comprising a pharmaceutical carrier.

8. The formulation of claim 6, further comprising an additional therapeutic agent.

9. The formulation of claim 8, wherein the therapeutic agent comprises a chemotherapy agent, a radiation therapy agent, an immunotherapy agent, or a hormone therapy agent.

10. The formulation of claim 9, wherein the radiation therapy agent is actinium-225 (Ac.sup.225), bismuth-213 (Bi.sup.213), boron-10 (B.sup.10)+neutron therapy, holmium-166 (Ho.sup.166), iodine-125 (I.sup.125), iodine-131 (I.sup.133), iridium-192 (Ir.sup.192), lead-212 (Pb.sup.212), lutetium-177 (Lu.sup.177), rhenium-186 (Re.sup.186), samarium-153 (Sm.sup.153), strontium-89 (Sr.sup.89), or yttrium-90 (Y.sup.90).

11. The formulation of claim 9, wherein the immunotherapy agent is an antibody selected from the group consisting of rituximab, trastuzumab, gemtuzumab ozogamicin, alemtuzumab, ibritumomab tiuxetan, tositumomab, cetuximab, bevacizumab, panitumumab, ofatumumab, denosumab, ipilimumab, and brentuximab vedotin.

12. The formulation of claim 9, wherein the hormone therapy agent is tamoxifen, an aromatase inhibitor, anastrozole, letrozole, or fulvestrant.

13. The formulation of claim 9, wherein the chemotherapy agent is carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, methotrexate, paclitaxel, topotecan, vincristine, or vinblastine.

14. The formulation of claim 9, wherein the chemotherapy agent is a nutlin, sirolimus (rapamycin), or MG132.

15. The formulation of claim 6, wherein said cell is eukaryotic, mammalian, or human.

16. The formulation of claim 6, wherein said cell is characterized by a proliferative disorder.

17. The formulation of claim 16, wherein the cell proliferative disorder is cancer, Castleman Disease, Gestational Trophoblastic Disease, or myelodysplastic syndrome.

18. The formulation of claim 17, wherein the cancer is adrenal cortical cancer, anal cancer, bile duct cancer, bladder cancer, bone cancer, brain or a nervous system cancer, breast cancer, cervical cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer, esophageal cancer, Ewing family of tumor, eye cancer, gallbladder cancer, gastrointestinal carcinoid cancer, gastrointestinal stromal cancer, Hodgkin Disease, intestinal cancer, Kaposi Sarcoma, kidney cancer, large intestine cancer, laryngeal cancer, hypopharyngeal cancer, laryngeal and hypopharyngeal cancer, leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, lung carcinoid tumor, lymphoma, lymphoma of the skin, malignant mesothelioma, multiple myeloma, nasal cavity cancer, paranasal sinus cancer, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, oral cavity cancer, oropharyngeal cancer, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, adult soft tissue sarcoma, skin cancer, basal cell skin cancer, squamous cell skin cancer, basal and squamous cell skin cancer, melanoma, stomach cancer, small intestine cancer, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, uterine cancer, vaginal cancer, vulvar cancer, Waldenstrom Macroglobulinemia, or Wilms Tumor.

19. The formulation of claim 18, wherein the cancer is primary or metastatic.

20. The formulation of claim 18, wherein the cancer occurs in a child or an adult.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXsearch
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480012001-05-07► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480022001-05-07► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Genzyme
LEMTRADA
alemtuzumab
INJECTABLE;INJECTION1039480032001-05-07► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Spectrum Pharms
ZEVALIN
ibritumomab tiuxetan
INJECTABLE; INJECTION1250190012002-02-19► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Imclone
ERBITUX
cetuximab
VIAL; INTRAVENOUS1250840012004-06-18► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXOrphansearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850012004-02-26► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXsearch
Genentech
AVASTIN
bevacizumab
VIAL; INTRAVENOUS1250850022004-02-26► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXsearch
Amgen
VECTIBIX
panitumumab
INJECTABLE; IV (INFUSION)1251470012006-09-27► Subscribe President and Fellows of Harvard College (Cambridge, MA) King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
United States of America2015328214Nov 19, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Cerilliant
McKinsey
AstraZeneca
Medtronic
US Department of Justice
Fuji
Moodys
Novartis
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot